Heart disease in women: Women with THIS common hormonal condition are at higher risk, new study finds

Recent medical reporting indicates a significant link between a common hormonal condition and an increased risk of heart disease in women. According to a report from The Times of India, a new study has identified that women living with this specific condition face a higher susceptibility to cardiovascular issues. This health development coincides with a broader shift in medical terminology regarding the disorder itself. Coverage from SNJ Today and theweek.in notes that the condition, previously known as Polycystic Ovary Syndrome (PCOS), has been renamed to PMOS. This nomenclature change is intended to better reflect the nature of the condition for patients and healthcare providers. Multiple outlets are tracking these developments, with theweek.in citing a study published in The Lancet.

This specific publication explains the medical reasoning behind the name change from PCOS to PMOS. The Lancet's findings are further amplified by theweek.in, which reports that one in eight women globally are affected by PMOS. Additional medical updates regarding these trends were also included in the Medical Bulletin published on July 24, 2026, by Medical Dialogues, suggesting a coordinated dissemination of this new clinical data across various medical news platforms and academic journals. The context for this trend involves a global health scale, as the prevalence of PMOS is notably high, impacting a substantial portion of the female population. The transition from PCOS to PMOS represents more than a simple linguistic update; according to SNJ Today, the new name carries specific implications for how patients understand their diagnosis. By linking this hormonal condition to heart disease, the new study highlighted by The Times of India suggests that the condition's impact extends beyond reproductive or hormonal health and into the realm of critical cardiovascular risk management for women worldwide.

Looking ahead, the focus remains on the implications of the Lancet study and the adoption of the PMOS terminology in clinical practice. Coverage indicates that the primary area of observation will be how the identification of heart disease risk changes the treatment approach for the one in eight women globally affected by the condition. While the provided coverage does not specify the exact physiological reason for the heart disease link, the shift in naming and the focus on cardiovascular risks suggest a new era of monitoring for those diagnosed with PMOS. Future reports will likely follow the integration of these findings into global health guidelines.